CIK 0001778922
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
SpyGlass Pharma, Inc.
Sign in to watch- Ticker
- SGP
- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 833044245
- Phone
- +1 949-284-6904
- Business address
- 15326 ALTON PARKWAY, IRVINE, CA, 92618
- Former names
- SpyGlassPharma, Inc., SpyGlass Ophthalmics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-02-09 | Nielsen Kirk G. Director | Conversion | +359,255 | 3,145,619 | ||
| 2026-02-09 | Nielsen Kirk G. Director | Purchase | +165,000 | $16.00 | $2.6M | 3,310,619 |
| 2026-02-09 | Nielsen Kirk G. Director | Conversion · Series B Preferred Stock | −9,689,922 | 0 | ||
| 2026-02-09 | Nielsen Kirk G. Director | Conversion · Series C-1 Preferred Stock | −3,142,015 | 0 | ||
| 2026-02-09 | Nielsen Kirk G. Director | Conversion · Series C-2 Preferred Stock | −3,142,015 | 0 | ||
| 2026-02-09 | Nielsen Kirk G. Director | Conversion · Series D Preferred Stock | −2,059,573 | 0 | ||
| 2026-02-09 | Vensana Capital I GP, LLC 10% owner | Conversion | +1,690,230 | 1,690,230 | ||
| 2026-02-09 | Vensana Capital I GP, LLC 10% owner | Conversion | +548,067 | 2,238,297 | ||
| 2026-02-09 | Vensana Capital I GP, LLC 10% owner | Conversion | +548,067 | 2,786,364 | ||
| 2026-02-09 | Vensana Capital I GP, LLC 10% owner | Conversion | +359,255 | 3,145,619 | ||
| 2026-02-09 | Vensana Capital I GP, LLC 10% owner | Purchase | +165,000 | $16.00 | $2.6M | 3,310,619 |
| 2026-02-09 | Vensana Capital I GP, LLC 10% owner | Conversion · Series B Preferred Stock | −9,689,922 | 0 | ||
| 2026-02-09 | Vensana Capital I GP, LLC 10% owner | Conversion · Series C-1 Preferred Stock | −3,142,015 | 0 | ||
| 2026-02-09 | Vensana Capital I GP, LLC 10% owner | Conversion · Series C-2 Preferred Stock | −3,142,015 | 0 | ||
| 2026-02-09 | Vensana Capital I GP, LLC 10% owner | Conversion · Series D Preferred Stock | −2,059,573 | 0 | ||
| 2026-02-05 | Khan Bilal Arshad Director | Grant or award · Stock Option (right to buy) | +13,700 | 13,700 | ||
| 2026-02-05 | Pujara Chetan Pratap Chief R&D Officer | Grant or award · Stock Option (right to buy) | +105,000 | 105,000 | ||
| 2026-02-05 | Dennewill James Robert Jr. Chief Operating Officer | Grant or award · Stock Option (right to buy) | +105,000 | 105,000 | ||
| 2026-02-05 | Mooney Patrick H. Chief Executive Officer | Grant or award · Stock Option (right to buy) | +300,000 | 300,000 | ||
| 2026-02-05 | Kahook Malik Y. See remarks | Grant or award · Stock Option (right to buy) | +105,000 | 105,000 |
Page 8 of 9 · 169 trades